Expression Analysis Relocates to Larger Laboratory Facility While Expanding its Genomic Services and Staff
News Feb 26, 2007
Expression Analysis, Inc. has announced that it has relocated its GLP-compliant laboratory to a larger facility in Durham, NC. The company has increased its staff and expanded the service offerings to meet the needs of its growing client base.
According to Company, the new facility, located on 4324 South Alston Avenue in Durham, NC, provides a three-fold increase in the amount of laboratory space.
Dr. Thomas Goralski, Vice President of Laboratory Operations said, “Last year we tripled our capacity for Affymetrix GeneChip testing and dramatically increased both our gene expression and genotyping services. We quickly out grew our current facility and look forward to the new site.”
The larger facility will also enable the installation of new equipment required for higher throughput Affymetrix testing as well as complementary services using other platforms.
Mr. Steve McPhail, CEO of Expression Analysis said, “Our clients have requested a variety of solutions for their gene expression and genotyping studies. We are working to meet their needs by introducing new approaches for testing RNA and DNA specimens from formalin-fixed, paraffin-embedded tissues on the Affymetrix platform and by initiating genomic services using Illumina, Luminex and Applied Biosystems’ TaqMan® technology platforms.”
In the last six months, Expression Analysis doubled its laboratory and informatics personnel. The company also created a dedicated marketing team and added two experienced US sales representatives for pharmaceutical and biotechnology accounts.
Ms. Molly Gleizes was previously with two genomic bioinformatics companies. She will cover clients in the Western U.S. region. Ms. Kellie Yarnell has eight years experience with genomics & molecular biology products as well as instrument sales. She will be responsible for clients in the Eastern U.S. region.
Mr. Jim Parina, Senior Director of Sales & Marketing said, “We are very excited about the addition of these two seasoned sales specialists to our team. Molly and Kellie both bring, to our rapidly growing company, the experience, skills and market knowledge we require in this period of explosive growth.”
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE